Factors affecting outcomes of alternating chemoradiotherapy for nasopharyngeal cancer

Annals of Otology, Rhinology and Laryngology

Volumn 123, Issue 7, 2014, Pages 509-516

  Ueno, Takayoshi ^a   Endo, Kazuhira ^a   Kondo, Satoru ^a   Wakisaka, Naohiro ^a   Murono, Shigeyuki ^a   Ito, Makoto ^a   Yoshizaki, Tomokazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Alternating chemoradiotherapy; Cisplatin; Nasopharyngeal cancer; Progression free survival; Weight loss

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; HEMOGLOBIN;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CERVICAL LYMPH NODE; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPARATIVE STUDY; DISTANT METASTASIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOXICITY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; MALE; MEDICATION COMPLIANCE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NECK DISSECTION; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERCEPTION DEAFNESS; PONS HEMORRHAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOSENSITIVITY; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84903532630     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003489414525122     Document Type: Article

References (27)

1. Sanada K, Kimura S, Fuhara T. In: Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents. Vol. 7. Lyon, France: IARC Scientific Publications; 1987:382-405.
2. Ho JHC. An epidemiological and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1978;4:183-197.
3. Wang DC, Cai WM, Hu VC. Long-term survival of 1035 cases of nasopharyngeal carcinoma. Cancer. 1988;61:2338-2341.
4. Qin DX, Hu YH, Yan JH, et al. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer. 1988;61:1117-1124.
5. Murono S, Yoshizaki T, Park CS, Furukawa M. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology. 1999;34(5):432-438.
6. Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx. Eighteen years' experience with megavoltage radiation therapy. Cancer. 1976;37:2605-2612.
7. Perez CA, Ackerman LV, Mill WB, Ogura JH, Powers WE. Cancer of the nasopharynx. Factors influencing prognosis. Cancer. 1969;24:1-17.
8. Wang CC, Meyer JE. Radiotherapeutic management of carcinoma of the nasopharynx. An analysis of 170 patients. Cancer. 1971;28:566-570.
9. Marcial VA, Hanley JA, Chang C, Davis LW, Moscol JA. Split-course radiation therapy of carcinoma of the nasopharynx: results of a national collaborative clinical trial of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:409-414.
10. Yoshizaki T, Kondo S, Wakisaka N, et al. Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma. Cancer Lett. 2013;337(1):1-7.
11. Geara FB, Sanguineti G, Tucker SL, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol. 1997;43:53-61.
12. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
13. Fuwa N, Ito Y, Kodaira T, et al. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points. Jpn J Clin Oncol. 2001;31:589-595.
14. Fuwa N, Shikama N, Hayashi N, et al. Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil-a phase II study. Oral Oncol. 2007;43:948-955.
15. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2003.
16. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966-6975.
17. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730-6738.
18. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008;71:1356-1364.
19. Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988;6:1401-1410.
20. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52:1238-1244.
21. Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011;47:656-666.
22. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631-637.
23. Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol. 2007;5:23-31.
24. Donaldson SS, Lenon RA. Alterations of nutritional status: impact of chemotherapy and radiation therapy. Cancer. 1979;43:2036-2052.
25. Suntharalingam M, Haas ML, Van Echo DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer. 2001;91:548-554.
26. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012;22(3):233-244.
27. Beaver ME, Matheny KE, Roberts DB, Myers JN. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg. 2001;125:645-648.